Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Data from 14 evaluable patients in an ongoing, open-label, dose-escalation Phase I trial showed that IV
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury